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Abstract. We aimed to investigate the association between adherence to the Mediterranean diet (MeDi) and Alzheimer’s disease
(AD) risk in a prospective study. Specifically, we analyzed reduced inflammation and improved metabolic profile as a potential
medium through which the MeDi reduced the risk of AD. During a 4-year follow-up, 118 incident AD cases were identified
among the 1219 non-demented elderly (age > 65) subjects who provided dietary information and blood samples at baseline.
We used high-sensitivity C-reactive protein (hsCRP) as an index of systemic inflammation, and fasting insulin and adiponectin
as indexes of metabolic profile. We investigated whether there was a change in the association between MeDi and incident AD
risk when the biomarkers were introduced into multivariable adjusted COX models. Better adherence to MeDi was associated
with lower level of hsCRP (p = 0.003), but not fasting insulin or adiponectin. Better adherence to MeDi was significantly
associated with lower risk for AD: compared to those in the lowest tertile of MeDi, subjects in the highest tertile had a 34% less
risk of developing AD (p-for-trend = 0.04). Introduction of the hsCRP, fasting insulin, adiponectin, or combinations of them
into the COX model did not change the magnitude of the association between MeDi and incident AD. Ultimately, the favorable
association between better adherence to MeDi and lower risk of AD did not seem to be mediated by hsCRP, fasting insulin, or
adiponectin. Other aspects of inflammatory and metabolic pathways not captured by these biomarkers, or non-inflammatory or
non-metabolic pathways, may be relevant to the MeDi-AD association.
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INTRODUCTION
The Mediterranean diet (MeDi), due to its correla-
tion with a low morbidity and mortality for many chron-
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ic diseases, has been widely recognized as a healthy
eating model [1]. In a recent prospective study, we
demonstrated that better adherence to the MeDi was
associated with lower risk of prevalent AD [2], incident
AD [3,4], incident MCI, or MCI conversion to AD [5].
The results were partially replicated in a French popu-
lation which demonstrated that better adherence to the
MeDi was associated with slower rates of cognitive
decline [6]. However, the underlying mechanisms by
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which the MeDi may reduce AD risk are not fully un-
derstood. In a previous study we demonstrated that the
association between MeDi and AD risk was not mediat-
ed through vascular pathways [2], leading us to explore
other possible pathways that might be involved.
Two closely related [7] and potentially important
mechanisms for AD are inflammation and metabolic
abnormalities [8,9]. Interestingly, mounting evidence
from both epidemiological and interventional studies
has revealed an effect of the MeDi on inflammatory
and metabolic biomarkers [10–18]. Therefore, it is
conceivable that the protective role of MeDi on AD
might be mediated by these two pathways involving
inflammation and metabolic abnormalities.
To our knowledge, whether and to what extent
biomarkers of inflammatory and metabolic pathways
explain the association between MeDi and AD risk
has not been formally investigated to date. To address
this question, we performed a prospective study to in-
vestigate possible change of the association between
baseline MeDi and incident AD (which would consti-
tute evidence of mediation) when high-sensitivity CPR
(hsCRP; as a biomarker of inflammation [19]), insulin
and adiponectin (as biomarkers of metabolic abnor-
malities [20,21]) were introduced in statistical mod-
els. Similar analysis was also performed to examine
whether the cross-sectional association between MeDi




The initial sample for this study included 2,778 par-
ticipants from a prospective study of aging and demen-
tia in Medicare-eligible northern Manhattan residents,
age 65 years and older (Washington/Hamilton Heights-
Inwood Columbia Aging Project II: WHICAP II). The
WHICAP II cohort represents a combination of con-
tinuing members of the cohort originally recruited in
1992 (WHICAP I; n = 604) and members of a new
cohort recruited between 1999 and 2001 (n = 2,174).
Both cohorts used similar sampling, assessments and
study procedures, which have been described in detail
elsewhere [2–5,22–24]. Briefly, at entry, a physician
elicited each subject’s medical and neurological histo-
ry and conducted a standardized physical and neuro-
logical examination. Each subject also underwent a
structured in-person interview including an assessment
of health and function and a neuropsychological bat-
tery [25]. Subjects were followed at intervals of ap-
proximately 1.5 years, repeating the baseline examina-
tion and consensus diagnosis [2–5,22–24].
Among the original 2,778 subjects, 345 were exclud-
ed due to prevalent dementia, 538 were excluded due
to lack of follow-up, and 543 were excluded due to lack
of a frozen blood sample. Thus, hsCRP, fasting in-
sulin and adiponectin were measured for the remaining
1,352 subjects in 2008 using frozen blood samples ob-
tained in the WHICAP II baseline examination during
1999-2001. The time of the blood collection was set as
the baseline for this study. An additional 113 subjects
were excluded because they did not have dietary infor-
mation available and 12 subjects were excluded due to
incomplete dietary information preventing a MeDi cal-
culation. A total of 8 subjects who developed incident
dementia other than AD during follow-up were further
excluded from the analysis. Thus, the initial analyt-
ic sample for both the cross-sectional and the survival
analyses comprised 1219 subjects.
Recruitment, informed consent, and study pro-
cedures were approved by the Institutional Review
Boards of Columbia Presbyterian Medical Center and
Columbia University Health Sciences and the New
York State Psychiatric Institute.
Diet and MeDi score
Dietary data regarding average food consump-
tion over the year before the baseline assessment
were obtained using a 61-item version of Willett’s
semi-quantitative food frequency questionnaire (SFFQ)
(Channing Laboratory, Cambridge, MA) [26]. Diet
information was available at baseline, the same date
as blood samples were collected, for 1,099 individuals
(90.2% of all subjects in this study). When dietary
information was not available on the same visit as the
baseline, the diet information closest to the baseline
was used. Thus, a total of 98 subjects with diet after
blood collection (on average 2.5 years, SD = 1.1 year,
after blood donation) and 22 with diet before blood
collection (on average 6.3 years, SD = 2.1 year, be-
fore blood donation) were used. We reported the re-
sults based on all 1,219 subjects, because 1) we have
previously showed the stability of MeDi over a period
of 8 years [3,4], and 2) we repeated analyses based on
the 1,099 subjects whose diet information and blood
samples were collected at the same time, and the re-
sults were unchanged (data not shown). The validity
(using two 7-day food records) and reliability (using
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two 3-month frequency assessments) of various com-
ponents of the SFFQ in WHICAP have been previously
reported [22–24].
We followed the most commonly described meth-
od [27] to construct the MeDi score as described in
our previous reports [2–5]. Individuals were assigned a
value of 1 for each beneficial component (fruits, vegeta-
bles, legumes, cereals, and fish) whose caloric-adjusted
consumption was at or above the gender-specific me-
dian, for each detrimental component (meat and dairy
products) whose caloric-adjusted consumption was be-
low the gender-specific median, for a ratio of monoun-
saturated fats to saturated fats above the median, and
for mild to moderate alcohol consumption (> 0 to <
30 g/d). The MeDi score was generated for each par-
ticipant by adding the scores in the food categories
(theoretically ranging 0-9) with higher score indicating
better adherence to the MeDi.
Cognitive performance at baseline
A composite cognitive Z-score was developed to
summarize cognitive performance as previously de-
scribed [28–32]. Briefly, we used factor analysis with
principal axis factoring and oblique rotation on 15 neu-
ropsychological test score variables [25] which grouped
cognitive performance into four factors: memory, lan-
guage, processing speed, and visual-spatial ability. Us-
ing cognitive test data from all WHICAP participants
at their initial visit, Z-scores for each of the cognitive
measures that comprised each factor were created and
then averaged to create a composite score for each fac-
tor. These factor domain scores were then averaged to
derive a composite cognitive Z-score. A higher Z-score
indicates better cognitive performance.
Alzheimer’s disease diagnosis
The process for diagnosing AD patients has been
previously reported [2–5]. Briefly, a consensus diagno-
sis for the presence or absence of dementia was made at
a diagnostic conference of neurologists and neuropsy-
chologists. Evidence of cognitive deficit (based on the
neuropsychological scores), and evidence of cognitive
and social-occupational function decline as compared
to the past were the criteria used for the diagnosis of
dementia as required by the DSM-III-R. For the diag-
nosis of probable or possible AD, the criteria of the
NINCDS-ADRDA were used. Dietary or biomarker
data were not available to the consensus panel and were
not considered in the diagnostic process.
Biomarker measurement
Baseline plasma hsCRP level was measured using
ELISA (Diagnostic systems laboratories, INC, Web-
ster, Texas). The assay sensitivity was 1.6 ng/ml,
the intra-assay and inter-assay coefficient of variations
(CVs) were 4.6% and 11.7%, respectively. Baseline
serum fasting insulin levels were measured using a
solid-phase chemiluminescent enzyme immunoassay
(Immulite, Diagnostic Products, Los Angeles, CA).
The intra-assay and inter-assay CVs were 4.7% and
8.2%, respectively. Baseline serum total adiponectin
levels were measured using radioimmunoassay (Lin-
co Research, Inc, St. Charles, MO). The intra-assay
CV was from 1.78% to 6.21%, and the inter-assay CV
was from 6.90% to 9.25%. Laboratory personnel were
blinded as to the dietary data and disease status of the
subjects.
Covariates
Age (years), education (years), caloric intake (kcal),
and body mass index (weight in kilograms divided by
height in square meters [kg/m2]) were used as continu-
ous variables. We also considered gender (men as ref-
erence), smoking status at baseline evaluation (current
smoker at baseline vs. non-smoker), and ethnic groups
(non-Hispanic Black, Hispanic, non-Hispanic White or
Other). Apolipoprotein E (APOE) genotype was used
as a dichotomous variable: absence of versus presence
of either 1 or 2 ε4 alleles. A modified version [4] of
the Charlson Index of Comorbidity [33] (referred to
as ‘comorbidity index’) was included as a continuous
variable.
Statistical analysis
Characteristics of the subjects
Circulating levels of hsCRP, fasting insulin, and
adiponectin had a skewed distribution and were trans-
formed to their natural logarithm. Characteristics of
patients, levels of biomarkers, and MeDi tertiles (MeDi
score 0–3 as the lowest, 4–5 as the middle, and 6–9 as
the highest tertile) were compared between AD cases
and dementia-free participants using t-test for continu-
ous variables, and chi-square test for categorical vari-
ables. Characteristics of patients were also compared
according to the tertiles of MeDi using linear regression
models for continuous variables, and chi-square test for
categorical variables. Spearman correlation was run to
examine the relationship between the 3 log-transformed
biomarkers.
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Associations between the biomarkers and MeDi score
To test the associations between the biomarkers and
MeDi score, linear regression models were used with
tertiles of the MeDi score used as an ordinal indepen-
dent variable to test the linear trend.
Cross-sectional data analysis
To test the associations between the biomarkers and
baseline cognitive score, linear regression models, both
unadjusted and adjusted for social-demographic covari-
ates, including age, gender, race, and education, were
used. Tertiles of the biomarkers were used as an ordinal
independent variable to test the linear trend.
Similar regression analysis adjusted for age, gender,
race, and education was also done to examine the asso-
ciation between MeDi and cognitive score.
To test whether biomarkers mediate the association
between MeDi and cognitive performance, we eval-
uated the change of β coefficient of MeDi when the
biomarkers were added to the regression model adjust-
ed for age, gender, race, and education. Changes of the
β coefficient values of greater than 15% were consid-
ered evidence of mediation by the variable added to the
model [34].
Longitudinal data analysis
To test the association between the biomarkers and
AD risk, COX proportional hazards models were
used with AD treated as the dichotomous outcome.
Biomarkers were treated as independent variables
which were entered into the models in tertiles. Tests
for trend with two-sided p-values were evaluated by
entering the tertile terms as an ordinal variable in the
COX model. The time-to-event variable was time from
recording of baseline to incident AD diagnosis for in-
cident patients; or to the time of the last follow-up for
subjects who did not develop dementia.
Similarly, we fit a COX model (original model), ad-
justed for age, gender, race, and education in the model,
to estimate the association between MeDi and AD risk.
The main predictor was MeDi score as a continuous
variable initially and in tertiles form subsequently. The
coefficient of MeDi was denoted as βt.
Finally, we tested whether the association between
MeDi and AD was mediated i) through inflammatory
pathway by including hsCRP (model 1); ii) through
metabolic pathways by including fasting insulin (model
2), adiponectin (model 3) or both (model 4); or iii)
through both inflammatory and metabolic pathways by
simultaneously including all three biomarkers (model
5) into the original COX model. The coefficient of
MeDi from all these 5 models is denoted as βi, i =
1–5.
The percentage of the association of MeDi and AD
that was mediated through either inflammation, or
metabolic factors, or both, was calculated as ∆β% =
100× (βt−βi)/ βt, i = 1–5. In order to maintain con-
sistent sample size in the analysis so that β coefficients
of different models can be compared appropriately, we
excluded 1) censored cases before the earliest event
in a stratum that were automatically excluded in COX
models; and 2) subjects missing values of covariates or
biomarkers.
We performed a supplementary analysis by addition-
ally adjusted for body mass index (BMI), smoking sta-
tus, alcohol drinking, caloric intake, medical comor-
bidity index, and APOE genotype in the COX mod-
els. The results were essentially unchanged (data not
presented in the current report).
All analyses were performed using PASW Statistics
17.0 (formerly SPSS Inc., Chicago, IL USA). Signifi-
cance level was set at 0.05.
RESULTS
Missing data analysis
Compared with subjects included in the analysis
(n = 1219), subjects who were excluded from the anal-
yses (n = 1559) were slightly older (76.7 vs. 79.2
years; p < 0.0001), had lower education (10.5 vs. 9.4
years; p < 0.0001), and more medical comorbidities
(1.9 vs. 2.2; p < 0.0001); were less likely to be smok-
ers (12% vs. 9%, p = 0.002) and White ( White 31%,
Black 30%, Hispanic 37%, Other 2% vs. White 24%,
Black 34%, Hispanic 41%, Other 1%; p < 0.0001);
and were more likely to be APOE ε4 carriers (25 vs.
31; p = 0.01).
Characteristics of subjects
During an average follow-up of 3.8 (SD, 1.3; range
= 1.1∼6.6) years, a total of 118 incident AD cases
were identified. Compared with subjects remaining
dementia-free during the follow-up, incident AD cases
were older, less educated, and had lower BMIs, were
most likely Hispanics (and less likely Whites) (Table 1).
AD cases tended to have higher median level of fasting
insulin than non-dementia subjects (p = 0.05). Com-
pared to subjects in the lowest tertile of MeDi, those
in the highest MeDi tertile were more likely to be non-
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Table 1
Demographic, clinical, and dietary characteristics for subjects with Alzheimer’s disease and non-demented subjects
Characteristics All Demented-free Incident AD p∗
(n = 1,219) (n = 1,101) (n = 118)
Mean age, year (SD) 76.7 (6.4) 76.3 (6.3) 80.7 (6.9) < 0.0001
Female gender, n (%) 812 (66.6) 736 (66.8) 76 (64.4) 0.59
Mean education, year (SD)+ 10.50 (4.7) 10.85 (4.5) 7.23 (5.1) < 0.0001
Race, n (%) < 0.0001
White 382 (31.3) 365 (33.2) 17 (14.4)
Black 359 (29.5) 326 (29.6) 33 (28.0)
Hispanic 457 (37.5) 390 (35.4) 67 (56.8)
Other 21 (1.7) 20 (1.8) 1 (0.8)
Presence of APOE ε4 allele, n (%) + 300 (25.1) 275 (25.4) 25 (21.6) 0.36
Smoker at baseline, n (%) 152 (12.5) 134 (12.1) 18 (15.3) 0.34
Mean medical comorbidity index (SD) 1.84 (1.4) 1.85 (1.4) 1.74 (1.4) 0.38
Mean caloric intake, Kcal/day (SD) 1499 (560) 1490 (552) 1585 (630) 0.08
Mean BMI, Kg/m2 (SD) + 27.7 (5.5) 27.8 (5.4) 26.3 (5.8) < 0.01
Mean MeDi (SD) 4.34 (1.7) 4.37 (1.7) 4.07 (1.8) 0.07
Tertiles of MeDi 0.09
Low, n (%) 400 (32.8) 351 (31.9) 49 (41.5)
Middle, n (%) 500 (41.0) 460 (41.8) 40 (33.9)
High, n (%) 319 (26.2) 290 (26.3) 29 (24.6)
Median hsCRP, mg/L(inter-quartile) 5.5 (2.8-14.0) 5.4 (2.8-14.0) 5.9 (1.9-14.7) 0.57
Median fasting insulin, mIU/ml (inter-quartile) 8.6 (3.0–19.9) 8.3 (3.0–19.7) 10.8 (3.0–25.5) 0.05
Median adiponectin, µg/ml (inter-quartile) 11.1 (7.0-18.0) 11.3 (7.0-18.0) 10.2 (6.8-18.5) 0.75
∗p values were from χ2 test for categorical variables, or one-way ANOVA test for continuous variables except for
hsCRP, insulin, and adiponectin for which the p values were from Kruskal-Wallis test.
+2 subjects missed information on education. +22 subjects missed information on APOE ε4. +4 subjects had
missing information on BMI.
smokers, Hispanics (and less likely Black) (Table 2).
The three biomarkers were correlated with each oth-
er: Spearman correlation coefficient between hsCRP
and insulin was 0.14, between hsCRP and adiponectin
−0.12, and between insulin and adiponectin−0.28, all
p < 0.0001.
Associations between MeDi and biomarkers
Compared to the lowest tertile of MeDi, subjects
in the highest MeDi tertile tended to have lower lev-
el of hsCRP (medians 4.6 mg/L vs. 6.7 mg/L, p for
trend =0.003). There was no difference between MeDi
tertiles regarding fasting insulin or adiponectin levels
(Table 2).
Cross-sectional analysis
Lower cognitive score, indicating worse cognitive pe-
rformance, was observed among subjects with higher
level of hsCRP (p = 0.01) or insulin (p = 0.001), or
with lower level of adiponectin (p < 0.001) (Supple-
mentary Table 1; available online:http://www.j-alz.com
/issues/22/vol22-2.html#supplementarydata03),but the
associations were attenuated and no longer significant
after adjusting for age, gender, race, cohort, and edu-
cation (Supplementary Table 1).
Better adherence to the MeDi was marginally associ-
ated with significantly better cognitive performance at
baseline: after adjusting for age, gender, race, and ed-
ucation, β = 0.013 (p = 0.05) for each unit increase of
MeDi score (Supplementary Table 2). When levels of
hsCRP, fasting insulin and adiponectin were, individu-
ally or together, added to the original model, the asso-
ciation between MeDi and cognitive performance were
essentially the same, with the changes in β coefficient
of MeDi less than 15% (Supplementary Table 2).
Longitudinal analysis
There was no difference between AD cases and
dementia-free subjects in hsCRP, fasting insulin or
adiponectin level (Table 1), and the biomarkers were
not associated with AD risk in COX models (p for trend
= 0.68 for hsCRP, 0.08 for fasting insulin, and 0.06
for adiponectin in unadjusted models; p for trend =
0.78 for hsCRP, 0.40 for fasting insulin, and 0.66 for
adiponectin in models adjusted for age, gender, educa-
tion, race).
As expected [3,4], better adherence to the MeDi
tended to be associated with significantly lower risk for
AD: after adjusting for age, gender, race, and educa-
tion, compared to subjects in the lowest tertile of MeDi
score, HR (95% CI) for subjects in the highest tertile
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Table 2
Demographic and clinical characteristics by Mediterranean diet score tertiles
Characteristics Low Middle High p∗
(N = 400) (N = 500) (N = 319)
MeDi score 0–3 4–5 6–9 /
Mean age, year (SD) 76.4 (6.6) 76.6 (6.4) 77.2 (6.2) 0.30
Female gender, n (%) 268 (67) 329 (66) 215 (67) 0.88
Mean education, year (SD)+ 10.6 (4.5) 10.6 (4.7) 10.2 (5.0) 0.51
Race, n (%) 0.007
White 135 (33.8) 150 (30.0) 97 (30.4)
Black 140 (35.0) 139 (27.8) 80 (25.1)
Hispanic 119 (29.8) 202 (40.4) 136 (42.6)
Other 6 (1.5) 9 (1.8) 6 (1.9)
Presence of APOE ε4 allele, n (%)+ 98 (24.9) 117 (24.1) 85 (26.7) 0.70
Smoker at baseline, n (%) 70 (18) 63 (13) 19 (6.0) < 0.0001
Mean medical comorbidity index (SD) 1.8 (1.4) 1.9 (1.4) 1.8 (1.4) 0.94
Mean caloric intake, Kcal/day (SD) 1509 (631) 1501 (534) 1485 (506) 0.85
Mean BMI, Kg/m2 (SD)+ 27.9 (5.8) 27.7 (5.2) 27.4 (5.4) 0.45
Incident AD, n (%) 49 (12) 40 (8) 29 (9) 0.09
Median hsCRP, mg/L(inter-quartile) 6.7 (3.5–17.0) 5.6 (2.8–13.4) 4.6 (2.4–13.7) 0.003
Median fasting insulin, mIU/ml (inter-quartile) 8.2 (3.0–20.5) 9.0 (3.0–22.5) 8.1 (3.0–17.7) 0.50
Median adiponectin, µg/mL(inter-quartile) 11.6 (7.1–18.3) 11.1 (6.8–17.9) 11.0 (6.9–17.9) 0.32
∗p-values for trend from logistic regression for binary variables, and from linear regression models for continuous variables
(including log transformed variables of hsCRP, fasting insulin and adiponectin), with tertiles of the MeDi score entering the
models as an ordinal variable. P-value for the categorical variables was from χ2 test.
+2 subjects missed information on education. +22 subjects missed information on APOE ε4. +4 subjects had missing
information on BMI.
was 0.66 (0.41–1.04) after multivariable adjustment, p
for trend = 0.04. Additional adjusting for other fac-
tors (including APOE4, comorbidity, smoking status,
caloric intake, and BMI), the results were essentially
the same: the HR (95% CI) comparing subjects in the
highest tertile to the lowest was 0.66 (0.41–1.06), p for
trend = 0.06.
Qualifications for mediators in general require asso-
ciations of the potential mediator with both the indepen-
dent variable (MeDi in this case) and the outcome (AD
risk in this case) [35]. Based on the above presented
results, we expected there would be no mediating effect
by hsCRP, fasting insulin and adiponectin. Neverthe-
less, we decided to proceed with the mediation analyses
because of (i) the association of some of the biomarkers
with MeDi and (ii) the strong evidence from the litera-
ture regarding associations between inflammatory and
metabolic biomarkers with both AD and the MeDi ad-
herence [7–18]. When levels of hsCRP, fasting insulin
and adiponectin were, individually or together, added
to the original model, the HRs did not change (Table 3).
The changes in β coefficient from the original model
to the 5 models were all less than 15% (Table 3).
DISCUSSION
In this prospective study, hsCRP, fasting insulin and
adiponectin did not mediate the association between
MeDi and AD risk. These results suggest that better ad-
herence to MeDi might not be associated with reduced
risk for AD via inflammatory or metabolic pathways.
Inflammation factors have been found to be associat-
ed with a higher risk for AD and cognitive decline [8].
Two large-scaled prospective studies showed baseline
blood levels of inflammatory markers are associated
with higher risk of incident AD [36,37]. Although
plasma hsCRP was not associated with risk of incident
AD in the present study, it was inversely associated
with baseline cognitive score (Supplementary Table 2),
especially in the memory and visual-spatial domains
as previously reported [32]. At the same time, several
intervention studies found that adherence to MeDi may
affect blood levels of inflammatory biomarkers [10,11,
18]. In the present study, median hsCRP level was
about 30% lower among subjects adhering to the high-
est compared to the lowest tertile of the MeDi, a mag-
nitude similar to those reported by other studies [12,
13]. Despite these, we found that hsCRP was not able
to explain a meaningful proportion of the association
between MeDi and either cognitive performance or risk
for incident AD, indicating that elevated hsCRP level
(possibly related to dietary behavior) might not mediate
the diet-AD association.
We also hypothesized that the association between
MeDi and AD could be mediated via fasting insulin
and adiponectin. On the one hand, association be-
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Table 3
Hazard ratios for subjects with Alzheimer disease and non-demented subjects by Mediterranean diet score in continuous
and tertile form adjusted for hsCRP, fasting insulin or adiponectin∗
Model+ MeDi HR (95% CI) β (∆β %)# p p-trend
original model MeDi continuous 0.87 (0.78–0.97) −0.143 0.01
MeDi tertile
Low 1 (reference)
Middle 0.57 (0.37–0.88) −0.559 0.01
High 0.66 (0.41–1.04) −0.420 0.08 0.04
Model 1 MeDi continuous 0.87 (0.78–0.97) −0.145 (−1.3%)
(original model + hsCRP) MeDi tertile
Low 1 (reference)
Middle 0.57 (0.37–0.88) −0.558 (0.2%) 0.01
High 0.66 (0.41–1.06) −0.413 (1.7%) 0.08 0.05
Model 2 MeDi continuous 0.87 (0.77–0.97) −0.145 (−1.3%) 0.01
(original model + insulin) MeDi tertile
Low 1 (reference)
Middle 0.56 (0.37–0.87) −0.574 (−2.7%) 0.01
High 0.66 (0.41–1.04) −0.419 (0.2%) 0.08 0.05
Model 3 MeDi continuous 0.87 (0.78–0.97) −0.138 (3.4%) 0.01
(original model + adiponectin) MeDi tertile
Low 1 (reference)
Middle 0.57 (0.37–0.88) −0.559 (0%) 0.01
High 0.67 (0.42–1.07) −0.400 (4.8%) 0.09 0.06
Model 4 MeDi continuous 0.87 (0.79–0.97) −0.140 (2.1%) 0.01
(original model + insulin + adiponectin) MeDi tertile
Low 1 (reference)
Middle 0.56 (0.36–0.86) −0.582 (−4.1%) 0.01
High 0.67 (0.42–1.07) −0.399 (5.0%) 0.09 0.06
Model 5 MeDi continuous 0.87 (0.78–0.97) −0.140 (2.1%) 0.01
(original model + all biomarkers) MeDi tertile
Low 1 (reference)
Middle 0.56 (0.36–0.86) −0.581 (−3%) 0.01
High 0.68 (0.42–1.08) −0.391 (6.9%) 0.10 0.06
∗All models limit to 1202 subjects without missing values on hsCRP, fasting insulin or adiponectin. Total number of incident
AD cases were 118 for all models in this table.
#The ∆β% for each tertile was calculated as compared to the corresponding tertile in the original model.
+Original model: adjusted for age, gender, education and race.
Model 1, 2, and 3: same as the original model, with additional adjustment for hsCRP, fasting insulin, and adiponectin level,
respectively.
Model 4: same as the original model, with additional adjustment for fasting insulin and adiponectin levels.
Model 5: same as the original model, with additional simultaneous adjustment for hsCRP, fasting insulin and adiponectin
levels.
tween metabolic abnormalities and risk of AD has been
demonstrated in multiple cohorts [9,38]. In our study,
fasting insulin tended to be inversely associated with
cognitive score and AD cases tended to have higher
median level of fasting insulin than non-dementia sub-
jects, although insulin was not associated with risk of
AD in the survival analysis adjusted for demographic
covariates. Adiponectin was neither associated with
baseline cognitive score nor associated with AD risk
after adjusting for demographic covariates. On the oth-
er hand, there are intervention studies reporting signif-
icant reductions in serum insulin in groups assigned
to MeDi [10,16], and cross-sectional studies reporting
MeDi-like dietary patterns [14,17] positively associat-
ed with adiponectin levels. However, the association
between MeDi and fasting insulin and adiponectin was
not always consistent, as one intervention study failed
to show a change of serum insulin level after 1-year of
MeDi-type intervention [39], and no intervention study
has been done on the association between MeDi and
adiponectin. Nevertheless, in the current study, neither
fasting insulin nor adiponectin was associated with Me-
Di, which might partly explain the finding that neither
of the two biomarkers was able to explain a meaningful
proportion of the association between MeDi and AD,
or the association between MeDi and baseline cogni-
tive score. Therefore, it seems that the potential medi-
ating role of fasting insulin and adiponectin needs to be
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further explored only when more consistent evidence
are available supporting the existence of an association
between MeDi with fasting insulin and adiponectin.
Other potential explanations for the null results
of our study include that hsCRP may not capture
the full inflammation pathway, and fasting insulin
and adiponectin may not fully capture all the related
metabolic changes. For example, one study found in-
creased levels ofα1-antichymotrypsin (α1-ACT) along
with occasional detection of interleukin-6 (IL-6) might
be peripheral markers of the “acute reaction” in the
brain, while hsCRP was not [40]. In a prospective
study in Rotterdam, high levels of α1-ACT and IL-6
were associated with an increased risk of dementia to a
higher extent than hsCRP [37].
Alternatively, other biological mechanisms may be
responsible for the MeDi-AD association. Growing
evidence implicates oxidative damage in the pathogen-
esis of AD [41]. The MeDi contains high concentra-
tions of complex phenols and other substances with an-
tioxidant properties (such as vitamins C, vitamins E,
and carotenoids), and may reduce markers of oxidative
stress such as isoprostanes [42]. Therefore, the MeDi
could be capturing the composite influence of dietary
antioxidants and this could, at least partially, explain
the association with a lower risk of AD. Similarly, vas-
cular variables are also likely to be in the causal path-
way between MeDi and AD considering the strong ev-
idence relating the MeDi to lower risk of vascular risk
factors [43], which may contribute to increased risk of
AD [44]. Although our previous study using clinical
diagnosis of vascular diseases as vascular variables did
not suggest these variables as a potential mediators for
the association between MeDi and AD risk [2], other
more sensitive measurement of vascular events, such
as subclinical vascular change in magnetic resonance
imaging, need to be considered in future studies.
The study has limitations. It lacks repeated measure-
ment for hsCRP, insulin, and adiponectin. However, it
has been shown that circulating levels of hsCRP [45],
insulin [46], and adiponectin [46] are quite stable within
individuals over a period of 3 years. Another limitation
of the study was that the inflammatory and metabol-
ic pathways may not be fully captured since other
biomarkers of these two pathways were not measured.
Participants with loss of follow-up or lack of blood
samples were different from the remaining participants
with regard to some AD risk factors. Although we ad-
justed for all the above factors in our models, exclud-
ing these subjects may have introduced selection bias.
A common limitation of studies of diet and disease is
misclassification of exposure due to limited accuracy
in assessing diet using SFFQ. In prospective studies,
though, exposure measurement error can usually be as-
sumed to be nondifferential with respect to disease sta-
tus or to covariates used to adjust the multivariate risk
for AD, so the measurement error may actually bias the
magnitude of the association toward null [47]. Similar-
ly, the possibility of disease misclassification bias may
not be completely ruled out, despite the use of standard
criteria, the diagnostic expertise of our center, and the
thorough workup.
Our study is innovative in exploring the potential
mechanisms of the association between MeDi and AD
risk by examining the mediating role of inflammato-
ry and metabolic biomarkers in this relationship. The
study is prospective in design, thus limiting the pos-
sibility of reverse causality to a great extent. Further-
more, our previous reports of the same study popu-
lation have performed a series of sensitivity analyses
by either adjusting baseline Clinical Dementia Rating
score or excluding subjects with mild cognitive deficits
at baseline and with less than 2 years of follow-up, and
the association between MeDi and risk of AD did not
change materially, suggesting that, although we cannot
completely exclude it, it is less likely that the degree of
adherence to MeDi was affected by early, subclinical
dementia process [3,4]. Dietary data were collected
with a previously validated instrument that has been
used widely in epidemiological studies [48]. The di-
agnosis of AD took place in a university hospital with
expertise in dementia and was based on comprehensive
assessment and standard research criteria. Information
about various potential AD risk factors has been care-
fully collected, recorded, and adjusted for in the analy-
ses. The study is community-based and the population
is multiethnic, increasing the external validity of the
findings.
In summary, the lower risk of AD associated with
better adherence to MeDi observed in this study popu-
lation does not seem to be mediated by hsCRP, fasting
insulin or adiponectin, suggesting that better adherence
to MeDi might not reduce risk for AD via inflammatory
or metabolic pathways, or that the used biomarkers do
not fully capture the corresponding pathways.
ACKNOWLEDGMENTS
Federal NIA grants P01-AG07232 and AG028506;
Alzheimer’s Association grant IIRG-09-133014.
Authors’ disclosures available online (http://www.j-
alz.com/disclosures/view.php?id=519).
Y. Gu et al. / Mediterranean Diet, Biomarkers and AD 491
REFERENCES
[1] Roman B, Carta L, Martinez-Gonzalez MA, Serra-Majem L
(2008) Effectiveness of the Mediterranean diet in the elderly.
Clin Interv Aging 3, 97-109.
[2] Scarmeas N, Stern Y, Mayeux R, Luchsinger JA (2006)
Mediterranean diet, Alzheimer disease, and vascular media-
tion. Arch Neurol 63, 1709-1717.
[3] Scarmeas N, Luchsinger JA, Schupf N, Brickman AM,
Cosentino S, Tang MX, Stern Y (2009) Physical activity, diet,
and risk of Alzheimer disease. JAMA 302, 627-637.
[4] Scarmeas N, Stern Y, Tang MX, Mayeux R, Luchsinger JA
(2006) Mediterranean diet and risk for Alzheimer’s disease.
Ann Neurol 59, 912-921.
[5] Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N,
Luchsinger JA (2009) Mediterranean diet and mild cognitive
impairment. Arch Neurol 66, 216-225.
[6] Feart C, Samieri C, Rondeau V, Amieva H, Portet F, Dartigues
JF, Scarmeas N, Barberger-Gateau P (2009) Adherence to a
Mediterranean diet, cognitive decline, and risk of dementia.
JAMA 302, 638-648.
[7] Haffner SM (2003) Insulin resistance, inflammation, and the
prediabetic state. Am J Cardiol 92, 18J-26J.
[8] Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM,
Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch
CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G,
Lue L, Mrak R, Mackenzie IR, McGeer PL, O’Banion MK,
Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R,
Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel
FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G,
Wyss-Coray T (2000) Inflammation and Alzheimer’s disease.
Neurobiol Aging 21, 383-421.
[9] Luchsinger JA, Tang MX, Shea S, Mayeux R (2004) Hyperin-
sulinemia and risk of Alzheimer disease. Neurology 63, 1187-
1192.
[10] Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F,
Giugliano G, D’Armiento M, D’Andrea F, Giugliano D (2004)
Effect of a Mediterranean-Style Diet on Endothelial Dysfunc-
tion and Markers of Vascular Inflammation in the Metabolic
Syndrome: A Randomized Trial. JAMA 292, 1440-1446.
[11] Estruch R, Martinez-Gonzalez MA, Corella D, Salas-Salvado
J, Ruiz-Gutierrez V, Covas MI, Fiol M, Gomez-Gracia E,
Lopez-Sabater MC, Vinyoles E, Aros F, Conde M, Lahoz C,
Lapetra J, Saez G, Ros E (2006) Effects of a Mediterranean-
style diet on cardiovascular risk factors: a randomized trial.
Ann Intern Med 145, 1-11.
[12] Chrysohoou C, Panagiotakos DB, Pitsavos C, Das UN, Ste-
fanadis C (2004) Adherence to the Mediterranean diet atten-
uates inflammation and coagulation process in healthy adults:
The ATTICA Study. J Am Coll Cardiol 44, 152-158.
[13] Fung TT, McCullough ML, Newby P, Manson JE, Meigs JB,
Rifai N, Willett WC, Hu FB (2005) Diet-quality scores and
plasma concentrations of markers of inflammation and en-
dothelial dysfunction. Am J Clin Nutr 82, 163-173.
[14] Fragopoulou E, Panagiotakos DB, Pitsavos C, Tampourlou
M, Chrysohoou C, Nomikos T, Antonopoulou S, Stefanadis
C (2009) The association between adherence to the Mediter-
ranean diet and adiponectin levels among healthy adults: the
ATTICA study. J Nutr Biochem 21, 285-289.
[15] Mantzoros CS, Williams CJ, Manson JE, Meigs JB, Hu FB
(2006) Adherence to the Mediterranean dietary pattern is pos-
itively associated with plasma adiponectin concentrations in
diabetic women. Am J Clin Nutr 84, 328-335.
[16] Jula A, Marniemi J, Huupponen R, Virtanen A, Rastas M,
Ronnemaa T (2002) Effects of diet and simvastatin on serum
lipids, insulin, and antioxidants in hypercholesterolemic men:
a randomized controlled trial. JAMA 287, 598-605.
[17] Yannakoulia M, Yiannakouris N, Melistas L, Kontogianni
MD, Malagaris I, Mantzoros CS (2008) A dietary pattern char-
acterized by high consumption of whole-grain cereals and low-
fat dairy products and low consumption of refined cereals is
positively associated with plasma adiponectin levels in healthy
women. Metabolism 57, 824-830.
[18] Mena MP, Sacanella E, Vazquez-Agell M, Morales M, Fito M,
Escoda R, Serrano-Martinez M, Salas-Salvado J, Benages N,
Casas R, Lamuela-Raventos RM, Masanes F, Ros E, Estruch
R (2009) Inhibition of circulating immune cell activation: a
molecular antiinflammatory effect of the Mediterranean diet.
Am J Clin Nutr 89, 248-256.
[19] Ridker PM, Morrow DA (2003) C-reactive protein, inflamma-
tion, and coronary risk. Cardiol Clin 21, 315-325.
[20] Laakso M (1993) How good a marker is insulin level for insulin
resistance? Am J Epidemiol 137, 959-965.
[21] Trujillo ME, Scherer PE (2005) Adiponectin–journey from
an adipocyte secretory protein to biomarker of the metabolic
syndrome. J Intern Med 257, 167-175.
[22] Luchsinger JA, Tang MX, Shea S, Mayeux R (2002) Caloric
intake and the risk of Alzheimer disease. Arch Neurol 59,
1258-1263.
[23] Luchsinger JA, Tang MX, Shea S, Mayeux R (2003) Antioxi-
dant vitamin intake and risk of Alzheimer disease. Arch Neurol
60, 203-208.
[24] Luchsinger JA, Tang MX, Siddiqui M, Shea S, Mayeux R
(2004) Alcohol intake and risk of dementia. J Am Geriatr Soc
52, 540-546.
[25] Stern Y, Andrews H, Pittman J, Sano M, Tatemichi T, Lantigua
R, Mayeux R (1992) Diagnosis of dementia in a heterogeneous
population. Development of a neuropsychological paradigm-
based diagnosis of dementia and quantified correction for the
effects of education. Arch Neurol 49, 453-460.
[26] Willett WC, Sampson L, Stampfer MJ, Rosner B, Bain C,
Witschi J, Hennekens CH, Speizer FE (1985) Reproducibility
and validity of a semiquantitative food frequency question-
naire. Am J Epidemiol 122, 51-65.
[27] Trichopoulou A, Costacou T, Bamia C, Trichopoulos D (2003)
Adherence to a Mediterranean diet and survival in a Greek
population. N Engl J Med 348, 2599-2608.
[28] Manly JJ, Bell-McGinty S, Tang MX, Schupf N, Stern Y,
Mayeux R (2005) Implementing diagnostic criteria and esti-
mating frequency of mild cognitive impairment in an urban
community. Arch Neurol 62, 1739-1746.
[29] Manly JJ, Tang MX, Schupf N, Stern Y, Vonsattel JP, Mayeux
R (2008) Frequency and course of mild cognitive impairment
in a multiethnic community. Ann Neurol 63, 494-506.
[30] Siedlecki KL, Honig LS, Stern Y (2008) Exploring the struc-
ture of a neuropsychological battery across healthy elders and
those with questionable dementia and Alzheimer’s disease.
Neuropsychology 22, 400-411.
[31] Scarmeas N, Albert SM, Manly JJ, Stern Y (2006) Education
and rates of cognitive decline in incident Alzheimer’s disease.
J Neurol Neurosurg Psychiatry 77, 308-316.
[32] Noble JM, Manly JJ, Schupf N, Tang MX, Mayeux R,
Luchsinger JA (2010) Association of C-reactive protein with
cognitive impairment. Arch Neurol 67, 87-92.
[33] Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A
new method of classifying prognostic comorbidity in longitu-
492 Y. Gu et al. / Mediterranean Diet, Biomarkers and AD
dinal studies: development and validation. J Chronic Dis 40,
373-383.
[34] Hosmer DW, Lemeshow S (1999) Interpretation of a fitted pro-
portional hazards regression model; Multiple-covariate mod-
els In Applied survival analysis: regression modeling of time
to event data John Wiley and Sons, Inc., New York, pp. 129-
137.
[35] MacKinnon DP, Lockwood CM, Hoffman JM, West SG,
Sheets V (2002) A comparison of methods to test mediation
and other intervening variable effects. Psychol Methods 7, 83-
104.
[36] Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer
LJ (2002) Early inflammation and dementia: a 25-year follow-
up of the Honolulu-Asia Aging Study. Ann Neurol 52, 168-
174.
[37] Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg
A, van Swieten JC, Stijnen T, Hofman A, Witteman JC, Bretel-
er MM (2004) Inflammatory proteins in plasma and the risk
of dementia: the rotterdam study. Arch Neurol 61, 668-672.
[38] Kopf D, Frolich L (2009) Risk of incident Alzheimer’s disease
in diabetic patients: a systematic review of prospective trials.
J Alzheimers Dis 16, 677-685.
[39] Michalsen A, Lehmann N, Pithan C, Knoblauch NT, Moe-
bus S, Kannenberg F, Binder L, Budde T, Dobos GJ (2006)
Mediterranean diet has no effect on markers of inflammation
and metabolic risk factors in patients with coronary artery
disease. Eur J Clin Nutr 60, 478-485.
[40] Licastro F, Morini MC, Polazzi E, Davis LJ (1995) Increased
serum alpha 1-antichymotrypsin in patients with probable
Alzheimer’s disease: an acute phase reactant without the pe-
ripheral acute phase response. J Neuroimmunol 57, 71-75.
[41] Pratico D (2002) Alzheimer’s disease and oxygen radicals:
new insights. Biochem Pharmacol 63, 563-567.
[42] Sanchez-Moreno C, Cano MP, de Ancos B, Plaza L, Olmedil-
la B, Granado F, Martin A (2006) Mediterranean vegetable
soup consumption increases plasma vitamin C and decreases
F2-isoprostanes, prostaglandin E2 and monocyte chemotactic
protein-1 in healthy humans. J Nutr Biochem 17, 183-189.
[43] Singh RB, Dubnov G, Niaz MA, Ghosh S, Singh R, Rastogi
SS, Manor O, Pella D, Berry EM (2002) Effect of an Indo-
Mediterranean diet on progression of coronary artery disease
in high risk patients (Indo-Mediterranean Diet Heart Study):
a randomised single-blind trial. Lancet 360, 1455-1461.
[44] Breteler MM (2000) Vascular risk factors for Alzheimer’s dis-
ease: an epidemiologic perspective. Neurobiol Aging 21, 153-
160.
[45] Gu Y, Zeleniuch-Jacquotte A, Linkov F, Koenig KL, Liu M,
Velikokhatnaya L, Shore RE, Marrangoni A, Toniolo P, Lok-
shin AE, Arslan AA (2009) Reproducibility of serum cy-
tokines and growth factors. Cytokine 45, 44-49.
[46] Kaplan RC, Ho GY, Xue X, Rajpathak S, Cushman M, Ro-
han TE, Strickler HD, Scherer PE, Anastos K (2007) Within-
individual stability of obesity-related biomarkers among wom-
en. Cancer Epidemiol Biomarkers Prev 16, 1291-1293.
[47] Schatzkin A, Subar AF, Moore S, Park Y, Potischman N,
Thompson FE, Leitzmann M, Hollenbeck A, Morrissey KG,
Kipnis V (2009) Observational epidemiologic studies of nutri-
tion and cancer: the next generation (with better observation).
Cancer Epidemiol Biomarkers Prev 18, 1026-1032.
[48] Willett W, Lenart E (1998) Reproducibility and Validity of
Food-Frequency Questionnaires In Nutritional Epidemiology,
Willett W, ed. Oxford University Press, New York, pp. 101-
147.
